The researcher is Saul Yedgar, who is the Walter and Greta Stiel Professor of Heart Studies at the Institute for Medical Research Israel-Canada at the Hebrew University Faculty of Medicine.
Inflammatory/allergic diseases affect billions of people worldwide, and treatments for these conditions are a major focus of the pharmaceutical industry. The most common drugs currently used to treat these numerous diseases are steroids, which are potent but are associated with severe side effects. These include metabolic changes (weight gain, increased blood pressure, diabetes), organ-specific effects (glaucoma, cataracts, bone fragility), and even psychotrophic side effects (depression, psychosis).
For decades, alternatives, such as biological NSAIDs (non-steroidal alternative anti-inflammatory drugs) have been the focus of the pharmaceutical industry. The resulting drugs have been commercially successful, but have not produced genuine alternatives to steroids due to their limitations. Synthetic NSAIDs are less potent and have their own serious side effects, including cardiovascular disorders, stomach bleeding and respiratory disorders. The biological drugs are costly and, must be injected and have rare but very severe side effects.
Inflammatory/allergic diseases present different symptoms affecting different organs, such as skin inflammations (dermatitis, psoriasis); airway injury and allergy (asthma, cystic fibrosis, allergic rhinitis); osteoarthritis and rheumatoid arthritis; intestinal inflammation (ulcerative colitis, Crohn¡¦s disease); central nervous system inflammation (multiple sclerosis), as well as atherosclerosis and cancer metastasis.
What they have in common is that all of them share biochemical mechanisms. A key one among them is the action of an enzyme family (PLA2) that initiates the production of a cascade of pro-inflammatory mediators involved in the induction and propagation of the diverse inflammatory diseases.
In Prof. Yedgar¡¦s lab at the Hebrew University, he and his associates have designed and constructed an entirely novel synthetic generation of drugs that control the PLAƒ¢ activity and the subsequent cascade of pro-inflammatory mediators, thereby providing multi-functional, anti-inflammatory drugs (MFAIDs).
MFAIDs have shown excellent safety and were found efficient in treating diverse inflammatory/allergic conditions in animal models, using different ways of administration ¡V oral, rectal, intravenous, inhaled and injected. These conditions included sepsis, inflammatory bowel diseases, asthma and central nervous system inflammation.
In particular, in two clinical studies MFAIDs have been shown to be safe and efficient in treating contact dermatitis, when incorporated into skin cream, and allergic rhinitis, when administered as a nasal spray.
This platform technology has been exclusively licensed from the Hebrew University through the university¡¦s Yissum Technology Transfer Company to Morria Biopharmaceuticals PLC (a British company), which is currently developing these drugs to treat inflammatory diseases of the airways (hay-fever, cystic fibrosis), the skin (eczema), the eye (conjunctivitis) and the gut (colitis, Crohn¡¦s disease).
For his groundbreaking work, Prof. Yedgar was one of the winners of this year¡¦s Kaye Innovation Awards at the Hebrew University. The Kaye Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society. The awards were presented this year during the annual meeting of the Hebrew University Board of Governors.
(Photo of Prof. Yedgar available via e-mail upon request)
CONTACT:Jerry Barach, Hebrew University Foreign Press Liaison
Jerry Barach | Hebrew University of Jerusalem
Antimicrobial substances identified in Komodo dragon blood
23.02.2017 | American Chemical Society
New Mechanisms of Gene Inactivation may prevent Aging and Cancer
23.02.2017 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
23.02.2017 | Physics and Astronomy
23.02.2017 | Earth Sciences
23.02.2017 | Life Sciences